BLA 103946 · Sanofi Synthelabo
Elitek
Rasburicase · Intravenous
NovelOrphanLast checked: Nov 20, 2026Latest source record: Dec 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Jul 12, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
35
5 Phase 3, 1 recruiting
FAERS reports
2,475
2,236 serious, 683 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS See full prescribing information for complete boxed warning . Hypersensitivity Reactions: Elitek can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue Elitek if a serious hypersensitivity reaction occurs ( 4 , 5.1 , 6.2 ). Hemolysis: Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek if hemolysis occurs. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy ( 4 , 5.2 ). Methemoglobinemia: Elitek can result in methemoglobinemia in...
What it is approved for
From the label in effect Jul 30, 2026.
Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Elitek is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ( 1 ) Limitations of use: Elitek is indicated only for a single course of treatment. ( 1 ) Limitations of Use Elitek is indicated only for a single course of treatment [see Warnings and Precautions (5.1) ] .
Mechanism: In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2009 Supplement 5083 · Efficacy OrphanLabelLetter
- Jul 12, 2002 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
1 products under this application
- ELITEK · RASBURICASE 1.5MG/VIAL · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rasburicase" as an intervention, any sponsor and status, largest first.
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00230178 · 280 participants · Start Apr 2004 · Primary completion Dec 2007
Drug: Rasburicase (SR29142); Allopurinol · For: Tumor Lysis Syndrome; Cancer; Hyperuricemia
Sites: Berkeley, California; Los Angeles, California; Denver, Colorado · 15 sites in all
- Mature B-Cell Lymphoma And Leukemia Study IIIPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT01046825 · 128 participants · Start Sep 9, 2010 · Primary completion Aug 31, 2023
Drug: COPAD; COP, COPD M3, CYM and 1 more · For: Mature B-Cell Lymphoma
Sites: San Diego, California; Memphis, Tennessee; Cairo, Egypt · 4 sites in all
- Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated HyperuricemiaPivotal-lookingCompleted
Virchow GroupIndustry
NCT00921375 · 100 participants · Start Feb 2010 · Primary completion Dec 2011
Drug: TULY · For: Hyperuricemia
Sites: Hyd, India
Children's Oncology GroupResearch network
NCT00057811 · 97 participants · Start Jun 2004 · Primary completion Oct 2009
Drug: doxorubicin hydrochloride; cyclophosphamide and 11 more · For: Childhood Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma and 9 more
Sites: Arcadia, California
National Institute on Aging (NIA)NIH
NCT01323335 · 97 participants · Start Mar 31, 2009 · Primary completion Jan 31, 2014
Drug: IV Uric Acid; IV Rasburicase · For: Healthy Volunteers
Sites: Baltimore, Maryland
SanofiSanofi (SNY)
NCT00230217 · 94 participants · Start Mar 2004 · Primary completion Jul 2006
Drug: Rasburicase (SR29142) · For: Tumors; Hyperuricemia; Tumor Lysis Syndrome
Sites: Berkley, California; Denver, Colorado; Jacksonville, Florida · 7 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00628628 · 82 participants · Start Jan 2008 · Primary completion May 2012
Drug: As Needed Rasburicase; Fixed Dose Rasburicase · For: Tumor Lysis Syndrome
Sites: Houston, Texas
- Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade LymphomaPivotal-lookingCompleted
Goethe UniversityAcademic, hospital or other
NCT00199043 · 80 participants · Start May 2003 · Primary completion May 2008
Drug: Allopurinol; Rasburicase · For: Adult Acute Lymphocytic Leukemia; High-grade Lymphoma
Sites: Frankfurt, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- tumour lysis syndrome364
- febrile neutropenia217
- off label use216
- acute kidney injury148
- pyrexia147
- drug ineffective140
- neutropenia137
- cytokine release syndrome133
- sepsis104
- multiple organ dysfunction syndrome103
- anaemia96
- respiratory failure95
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 18 |
| 2008 | 12 |
| 2009 | 11 |
| 2010 | 27 |
| 2011 | 40 |
| 2012 | 54 |
| 2013 | 57 |
| 2014 | 63 |
| 2015 | 76 |
| 2016 | 96 |
| 2017 | 139 |
| 2018 | 243 |
| 2019 | 155 |
| 2020 | 195 |
| 2021 | 251 |
| 2022 | 222 |
| 2023 | 199 |
| 2024 | 229 |
| 2025 | 190 |
| 2026 | 178 |
Recalls
1 FDA enforcement reports for this application.
Aug 10, 2020 · Class II · Ongoing
Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elitek (Rasburicase)
2024 spending
$1.9M
Beneficiaries
203
228 claims
Per beneficiary
$9,453
$1,366.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $196,315 |
| 2021 | $207,138 |
| 2022 | $259,677 |
| 2023 | $571,449 |
| 2024 | $1,918,983 |
Part B: Elitek (Rasburicase) · HCPCS J2783
2024 spending
$10.6M
Beneficiaries
1,455
2,076 claims
Per beneficiary
$7,297
2024 ASP limit $369.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,184,840 |
| 2021 | $13,796,621 |
| 2022 | $13,330,219 |
| 2023 | $11,795,774 |
| 2024 | $10,616,814 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Rasburicase induced methemoglobinemia: A systematic review of descriptive studies.
Vidhyashree BH, Zuber M, Taj S, et al. · J Oncol Pharm Pract 2022 · Systematic Review
- Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports.
Hammami MB, Qasim A, Thakur R, et al. · Ann Hematol 2024 · Systematic Review
- Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
Kydd AS, Seth R, Buchbinder R, et al. · J Rheumatol Suppl 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T, Thadanipon K, Ruenroengbun N, et al. · BMC Nephrol 2022 · Systematic Review, Network Meta-Analysis
- Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
Kimura K, Kanehira N, Takayanagi R, et al. · Biol Pharm Bull 2016 · Clinical Trial, Phase II
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.